Risk Factors for Appropriate Cardioverter-Defibrillator Shocks, Inappropriate Cardioverter-Defibrillator Shocks, and Time to Mortality in 549 Patients With Heart Failure

American Journal of Cardiology

Volumn 105, Issue 9, 2010, Pages 1336-1338

  Desai, Harit ^a   Aronow, Wilbert S ^a   Ahn, Chul ^b   Gandhi, Kaushang ^a   Hussain, Sadaf ^a   Lai, Hoang M ^a   Sharma, Mala ^a   Frishman, William H ^a   Cohen, Martin ^a   Sorbera, Carmine ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; DEFIBRILLATOR; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART PACING; HEART RIGHT VENTRICLE; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SHOCK; SMOKING; STEP WISE MULTIPLE REGRESSION;

AGED; CAUSE OF DEATH; ECHOCARDIOGRAPHY; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77950865082     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.12.057     Document Type: Article

References (13)

1. Goldenberg I., Moss A.J., McNitt S., Zareba W., Daubert J.P., Hall W.J., Andrews M.L., and Multicenter Automatic Defibrillator Implantation Trial-II Investigators. Cigarette smoking and the risk of supraventricular and ventricular tachyarrhythmias in high-risk cardiac patients with implantable cardioverter-defibrillators. J Cardiovasc Electrophysiol 17 (2006) 931-936
2. Desai H., Aronow W.S., Tsai F., Ahn C., Lai H.M., Amin H., Gandhi K., Frishman W.H., Cohen M., and Sorbera C. Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy. J Cardiovasc Pharmacol Ther 14 (2009) 176-179
3. Vyas A.K., Guo H., Moss A.J., Olshansky B., McNitt S.A., Hall W.J., Zareba W., Steinberg J.S., Fischer A., Ruskin J., Andrews M.L., and MADIT-II Research Group. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 769-773
4. Mitchell L.B., Powell J.L., Gillis A.M., Kehl V., Hallstrom A.P., and AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs?. An analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
5. De Sutter J., Tavernier R., De Buyzere M., Jordaens L., and De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36 (2000) 766-772
6. Daubert J.P., Zareba W., Cannom D.S., McNitt S., Rosero S.Z., Wang P., Schuger C., Steinberg J.S., Higgins S.L., Wilber D.J., Klein H., Andrews M.L., Hall W.J., Moss A.J., and MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II. J Am Coll Cardiol 51 (2008) 1357-1365
7. Aronow W.S., Ahn C., and Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older men and women with abnormal versus normal left ventricular ejection fraction. Am J Cardiol 85 (2000) 1382-1384
8. Aronow WS, Frishman WH. Management of hypercholesterolemia in older persons. Cardiol Rev; in press.
9. Dickinson M.G., Ip J.H., Olshansky B., Hellkamp A.S., Anderson J., Poole J.E., Mark D.B., Lee K.L., Bardy G.H., and SCD-HeFT Investigators. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 153 (2007) 573-578
10. Lai H.M., Aronow W.S., Kruger A., Desai H., Amin H., Frishman W.H., Cohen M., and Sorbera C. Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators. Am J Cardiol 102 (2008) 77-78
11. Thibodeau J.B., Pillarisetti J., Khumri T.M., Jones P.G., and Main M.L. Mortality rates and clinical predictors of reduced survival after cardioverter defibrillator implantation. Am J Cardiol 101 (2008) 861-864
12. The DAVID Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual chamber and VVI Implantable Defibrillator (DAVID) trial. JAMA 288 (2002) 3115-3123
13. Sukhija R., Aronow W.S., Sorbera C., Peterson S.J., Frishman W.H., and Cohen M. Mortality, left ventricular ejection fraction, and prevalence of new left ventricular wall motion abnormality at long-term follow-up in patients with implantable cardioverter defibrillators treated with biventricular pacing versus right ventricular pacing. Am J Ther 14 (2007) 328-330